Group 1 - Henriette Mersebach will step down as Executive Vice President of Research and Development and as a member of the Board of Management effective February 23, 2026, and will assist with the transition [1] - The decision to appoint a new head of R&D aims to enhance ALK's innovation efforts under the Allergy strategy, focusing on balancing core-business growth with expansion into adjacent allergy therapy areas [2] - Peter Halling, CEO, acknowledged Mersebach's contributions, including securing important regulatory approvals and advancing the peanut allergy program, while stating that a new leader is needed to drive the ambitious innovation strategy [3] Group 2 - ALK has initiated a search for a new head of R&D and appointed Henrik Jacobi, the former Head of R&D, as a special advisor to assist with evolving ALK's innovation model [3] - ALK is a global specialty pharmaceutical company focused on allergy, involved in the entire value chain of developing, sourcing, producing, and marketing products for diagnosing and treating respiratory allergies and severe allergic reactions [5]